Morgan Stanley Remains Bullish on Ascendis Pharma (ASND)

Ascendis Pharma A/S (NASDAQ:ASND) is one of the top high growth international stocks to buy right now. On September 8, Morgan Stanley analyst Maxwell Skor maintained a Buy rating on Ascendis Pharma A/S (NASDAQ:ASND) and set a price target of $250.00.

Ascendis Pharma A/S (NASDAQ:ASND) reported its fiscal Q2 2025 results on August 7, announcing €103.0 million in revenue for YORVIPATH and €50.7 million for SKYTROFA.

Jan Mikkelsen, Ascendis Pharma’s (NASDAQ:ASND) President and Chief Executive Officer, stated that the company is on the cusp of considerably transforming its financial profile and bringing its third high-value medicine to patients with the “robust global uptake of YORVIPATH and with TransCon CNP under U.S. FDA priority review.”

Headquartered in Hellerup, Denmark, Ascendis Pharma A/S (NASDAQ:ASND) is a biopharmaceutical company that develops drug candidates. It specializes in its TransCon technologies for the development of new therapies addressing unmet medical needs.

While we acknowledge the potential of ASND as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.